PD-(L)1 x VEGF bispecifics prove a big draw.
ApexOnco Front Page
Recent articles
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
The company reckons its immunotherapy could improve on Keytruda.
“We need all the capital we can get our hands on," the company states.
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
Sunmo succeeds in a setting very similar to Starglo's.
